Physician profile
Carl E Harder
NPI 1558635748
$1,967.51
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $630 · 2020: $112 · 2021: $131 · 2022: $218 · 2023: $452 · 2024: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $876.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $225.71 | 2019-2024 | Total30 |
| Johnson & Johnson Surgical Vision, INC. | $206.67 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $195.01 | 2019-2021 | |
| Biotissue Holdings INC. | $175.18 | 2023 | |
| Harrow Eye, LLC | $172.84 | 2024 | Vevye |
| Genentech USA, INC. | $124.74 | 2023 | Vabysmo |
| Coopervision INC. | $124.11 | 2019 | |
| Astellas Pharma US INC | $119.70 | 2023 | |
| Bausch & Lomb Americas INC. | $117.02 | 2022 | |
| Shire North American Group INC | $102.60 | 2019 | |
| Abbvie INC. | $100.80 | 2022 | |
| Ivantis, INC | $100.20 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $98.27 | 2024 | |
| Mallinckrodt Hospital Products INC. | $32.66 | 2023 | Acthar |
| Kala Pharmaceuticals, INC. | $31.76 | 2020-2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $23.68 | 2024 | Oxervate |
| Allergan, INC. | $16.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Harder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.